Payment overview · 2025
General Payments
$218.29
10 reported records · 5 companies
Healthcare provider profile · identity verified
Peter Alan Nutson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PFLUGERVILLE, TX · NPI 1720088206
Verified facts
What the public records show
CMS Open Payments records show Peter Alan Nutson, MD received $218.29 in general payments during 2025 across 10 reported records.
Exact Sciences Corporation accounted for 47.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $104.14 | 47.7% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.49 | 20.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$31.39 | 14.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.37 | 8.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.90 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $218.29 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $85.67 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $44.49 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $31.39 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 916 | 368 |
| Levothyroxine Sodium | Levothyroxine Sodium | 648 | 238 |
| Amlodipine Besylate | Amlodipine Besylate | 603 | 254 |
| Losartan Potassium | Losartan Potassium | 442 | 169 |
| Lisinopril | Lisinopril | 429 | 172 |
| Omeprazole | Omeprazole | 411 | 147 |
| Gabapentin | Gabapentin | 389 | 150 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 350 | 132 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 116 |
| Metformin Hcl | Metformin Hcl | 290 | 117 |
| Fluticasone Propionate | Fluticasone Propionate | 275 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 108 |
| Furosemide | Furosemide | 250 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 240 | 90 |
| Tizanidine Hcl | Tizanidine Hcl | 218 | 66 |
| Metformin Hcl Er | Metformin Hcl | 201 | 84 |
| Trazodone Hcl | Trazodone Hcl | 197 | 67 |
| Simvastatin | Simvastatin | 168 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 58 |
| Sertraline Hcl | Sertraline Hcl | 150 | 60 |
| Eliquis | Apixaban | 146 | 43 |
| Ozempic | Semaglutide | 142 | 38 |
| Celecoxib | Celecoxib | 140 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 44 |
| Potassium Chloride | Potassium Chloride | 137 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 50 |
| Tramadol Hcl | Tramadol Hcl | 129 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 127 | 52 |
| Clonazepam | Clonazepam | 125 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 46 |
| Alendronate Sodium | Alendronate Sodium | 113 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 45 |
| Alprazolam | Alprazolam | 112 | 20 |
| Carvedilol | Carvedilol | 110 | 44 |
| Prednisone | Prednisone | 110 | 75 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 42 |
| Trulicity | Dulaglutide | 103 | 27 |
| Meloxicam | Meloxicam | 98 | 40 |
| Montelukast Sodium | Montelukast Sodium | 97 | 31 |
| Famotidine | Famotidine | 89 | 26 |
| Jardiance | Empagliflozin | 86 | 39 |
| Glipizide Er | Glipizide | 75 | 31 |
| Ezetimibe | Ezetimibe | 73 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 49 |
| Donepezil Hcl | Donepezil Hcl | 70 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 17 |
| Mirtazapine | Mirtazapine | 66 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 22 |
| Allopurinol | Allopurinol | 65 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 23 |
| Valsartan | Valsartan | 64 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 62 | 21 |
| Myrbetriq | Mirabegron | 59 | 14 |
| Spironolactone | Spironolactone | 57 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | 18 |
| Glipizide | Glipizide | 54 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 19 |
| Valacyclovir | Valacyclovir Hcl | 51 | 18 |
| Glimepiride | Glimepiride | 50 | 20 |
| Pregabalin | Pregabalin | 49 | 19 |
| Buspirone Hcl | Buspirone Hcl | 48 | 22 |
| Clonidine Hcl | Clonidine Hcl | 48 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 23 |
| Humalog Kwikpen U-100 | Insulin Lispro | 48 | 18 |
| Ibuprofen | Ibuprofen | 47 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 13 |
| Finasteride | Finasteride | 46 | 20 |
| Ketoconazole | Ketoconazole | 46 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | 12 |
| Aripiprazole | Aripiprazole | 44 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 19 |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 40 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 32 |
| Chlorthalidone | Chlorthalidone | 37 | 12 |
| Lorazepam | Lorazepam | 37 | 11 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Ondansetron Odt | Ondansetron | 35 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 14 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 14 |
| Baclofen | Baclofen | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Atenolol | Atenolol | 26 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | 12 |
| Bupropion Xl | Bupropion Hcl | 25 | 12 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 16 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Estradiol | Estradiol | 24 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | 11 |
| Olanzapine | Olanzapine | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Azithromycin | Azithromycin | 22 | 21 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 13 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $218.29 · 10 records | Exact Sciences Corporation | Auvelity, Cologuard Collection Kit, Dexcom G6 Transmitter, INTELLIS ADAPTIVESTIM, REXULTI, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error